Clinical trials: Frontline
Follicular Lymphoma, Follicular Lymphoma, Grade 1
Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
The purpose of this study is to find out how successful ibrutinib is at putting follicular lymphoma into full remission. In this study, remission will be determined by achieving a normal PET scan after treatment.
- Conditions
- Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade IIIa
- Trial name
- NCT02966730
- Testing
- Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Langerhans Cell Histiocytosis
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body.
- Trial name
- NCT02670707
- Testing
- Cytarabine, Vinblastine/prednisone
- Where
- 11 sites in United States
- Volunteers
- 124 people
- Sponsor
- Baylor College of Medicine
High-Grade Lymphomas
HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy
The study is planned to compare the outcome of aggressive NHL patients in partial remission after four courses of front-line therapy, randomly assigned to receive either additional four courses of the same regimen or a modified…
- Trial name
- NCT00866203
- Testing
- HDS vs ProMECE/CytaBOM
- Where
- Italy
- Volunteers
- 441 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy.
- Conditions
- Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
- Trial name
- NCT05616624
- Testing
- ADI-PEG 20, Gemcitabine, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy.
- Trial name
- FASTER (NCT06974786)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Leukemia
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00096018
- Testing
- fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Cancer
FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study
This study aims to answer very important questions regarding the prevalence of somatic and germline mutations (sBRCAm and gBRCAm) in a population of newly diagnosed ovarian cancer patients from Latin America.
- Trial name
- FLABRA (NCT02984423)
- Where
- 27 sites in Argentina, Brazil and 4 more
- Volunteers
- 471 people
- Sponsor
- AstraZeneca
Indolent Lymphoma, Follicular Lymphoma
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
A Phase II Study of Pomalidomide Combined with Anti-CD20 Monoclonal Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Objective: This prospective, single-arm, Phase II trial aims to evaluate the efficacy and safety of…
- Conditions
- Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell Lymphoma
- Trial name
- NCT07609446
- Testing
- Pomalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Philadelphia Positive Acute Lymphoblastic Leukemia
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
The current standard treatment approach for young patients with Positive Acute Lymphoblastic Leukemia (Ph+ALL) is the combination of a chemotherapy protocol employing four to five cytotoxic agents typically used for ALL together…
- Trial name
- NCT01724879
- Testing
- Dasatinib
- Where
- 22 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Goethe University
Lymphoma, Large-Cell, Diffuse
Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
The aim of the protocol is to compare the outcome of patients with DLBCL stage II bulky, III or IV with 1 to 3 adverse prognostic factors according to the International prognostic index.
- Trial name
- NCT00561379
- Testing
- CHOP+RITUXIMAB, CEEP-RITUXIMAB
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Nantes University Hospital
Large B-cell Lymphoma
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have…
- Trial name
- ALPHA3 (NCT06500273)
- Testing
- cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide
- Where
- 85 sites in United States, Australia and 2 more
- Volunteers
- 250 people
- Sponsor
- Allogene Therapeutics
Cardiac Amyloidosis
Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
To prove the organ-reversing potential of thalidomide for amyloidosis with cardiac involvement
- Trial name
- TaPiOCA (NCT02966522)
- Testing
- Thalidomide, Dexamethasone
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Child Malnutrition, Breastfeeding
Impact of Behavior Change Communications and Market-based Approach to Delivering Micronutrient Powders on Stunting, Infant Feeding Practices and Anemia in Bangladesh
This complex evaluation of a large-scale program uses a cluster-randomized design where 20 geographic clusters (subdistricts) were randomized to study two sets of interventions.
- Conditions
- Child Malnutrition, Breastfeeding, Complementary Feeding, Childhood Anemia
- Trial name
- NCT01678716
- Testing
- EHC + BCC, Micronutrient powders, Mass media
- Where
- Bangladesh
- Volunteers
- 8,800 people, healthy volunteers welcome
- Sponsor
- International Food Policy Research Institute
Emotional Intelligence, Leadership
Emotional Intelligence Skills Health Leaders Need During Covid-19
Problem The study will address the problem that no studies have established the Emotional Intelligence (EI) skills required by leaders and managers to engage frontline healthcare professionals in crisis situation like Covid19 in…
- Conditions
- Emotional Intelligence, Leadership, Health Personnel Attitude, Covid-19
- Trial name
- NCT04694014
- Testing
- EI Open ended Pre-Survey and Semi Structured Interview, Behavioral and Cognitive Assessment, Geneva Emotional Competence Test (GECO)
- Where
- Kenya
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- African Wood Inc
Multiple Myeloma
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Phase III multicenter randomized, open-label study comparing the efficacy of a combined high dose chemotherapy using melphalan and bortezomib versus melphalan alone followed by stem cell transplant in frontline multiple myeloma…
- Trial name
- IFM2014-02 (NCT02197221)
- Testing
- Bortezomib-Melphalan, Melphalan
- Where
- 46 sites in Belgium, France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Toulouse
Chronic Lymphocytic Leukemia
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of bendamustine and rituximab (BR) followed by venetoclax for 12 months. The total time on therapy is 15 months.
- Trial name
- NCT03609593
- Testing
- Bendamustine, Venetoclax, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Nicole Lamanna
Chronic Lymphocytic Leukemia, CLL
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC).
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line
- Trial name
- NCT00628238
- Testing
- Lenalidomide and Rituximab
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
The purpose of this research study is to evaluate a new drug pembrolizumab in combination with chemotherapy, for the treatment of newly diagnosed Hodgkin lymphoma.
- Conditions
- Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma
- Trial name
- NCT03226249
- Testing
- Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Acute Myeloid Leukemia
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
The VERDI study is an investigator-initiated, multicenter, multicohort, phase II trial with combination of venetoclax + azacitidine for patients treated for AML under according to an intensive chemotherapy protocol (CETLAM-20)…
- Trial name
- VERDI (NCT06668558)
- Testing
- Azacitidine (AZA), Venetoclax
- Where
- 14 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00656448
- Testing
- Procrit
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center